Data shared from Phase 3 study on DUPIXENT treatment of atopic dermatitis

Regeneron Pharmaceutical Inc. and Sanofi recently presented the results of their one-year Phase 3 CHRONOS study, showing that investigational drug DUPIXENT combined with topical corticosteroids (TCS) achieved better results in treating uncontrolled moderate-to-severe atopic dermatitis (AD) than TCS alone.
"These new results build upon previous positive Phase 3 monotherapy data,” said Oregon Medical Research Center President Dr. Andrew Blauvelt, the principal investigator of the study. “In the CHRONOS study, DUPIXENT used with topical corticosteroids showed significantly greater clearance of skin lesions and overall disease severity compared to topical corticosteroids alone, which are commonly prescribed for moderate-to-severe atopic dermatitis."
The results, presented at the annual meeting of the American Academy of Dermatology (AAD), show that patients who received DUPIXENT in combination with TCS had significantly higher baseline improvements, improvements to intensity of patient-reported itch, improvements to the severity of their AD and improvements to their quality of life. AD is a common form of eczema and in its moderate-to-severe form can casus intense, persistent and debilitating itching, dryness, cracking redness, crusting and oozing.
"This study provides positive long-term data for DUPIXENT, which is important given atopic dermatitis is a chronic inflammatory disease,” Blauvelt said. “Additionally, the presentation highlights the critical role of IL-4 and IL-13 as drivers of this atopic condition."